Funder
National Key Technologies R&D Program
National Natural Science Foundation of China
Beijing Natural Science Foundation
National Science and Technology Major Projects for "Major New Drugs Innovation and Development"
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Cardone M, Garcia K, Tilahun ME, et al. A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. J Clin Invest. 2018;128:2819–32.
2. Dean L. Abacavir therapy and HLA-B*57:01 genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical genetics summaries [internet]. Bethesda: National Center for biotechnology information (US); .2012–.2015 Sep 1 [updated 2018 Apr 18].
3. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet. 2004;363:1253–63.
4. Siegfried NL, Van Deventer PJ, Mahomed FA, et al. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006;19:CD004535.
5. Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV. 2017;4:e536–46.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献